KYMERA THERAPEUTICS ($NASDAQ:KYMR) announced their financial performance for the second quarter of Fiscal Year 2023 on August 3 2023. Total revenue for the quarter amounted to USD 16.5 million, a 43.4% increase from the same period in the prior year. Net income for the quarter was reported as USD -38.8 million, a decrease from the previous year’s figure of -40.3 million.
Analysis – Kymera Therapeutics Intrinsic Value
GoodWhale has conducted an in-depth analysis of KYMERA THERAPEUTICS‘ well-being and the value of its stock. According to our proprietary Valuation Line, the fair value of a KYMERA THERAPEUTICS share stands at $34.3. However, the company’s stock is currently trading at $23.9, which implies that it is undervalued by 30.3%. This presents an opportunity for investors looking for a good deal on their investments. With this in mind, we believe that KYMERA THERAPEUTICS is a great buy at its current price. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Kymera Therapeutics. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Kymera Therapeutics. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Kymera Therapeutics. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Kymera Therapeutics are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The company is engaged in the discovery and development of first-in-class medicines to treat patients with severe and life-threatening diseases. Kymera Therapeutics Inc’s lead product candidate is KYM-001, which is in Phase I clinical trials for the treatment of patients with relapsed or refractory B-cell malignancies. The company’s competitors include Abionyx Pharma, Shattuck Labs Inc, and Prestige BioPharma Ltd.
– Abionyx Pharma ($LTS:0RAG)
Abionyx Pharma is a pharmaceutical company with a market cap of 52.78M as of 2022. The company has a Return on Equity of -37.6%. Abionyx Pharma is a company that focuses on the development and commercialization of innovative therapies for the treatment of cancer and other rare diseases.
Shattuck Labs Inc is a clinical-stage biopharmaceutical company. The company’s focus is on developing immunotherapy treatments for cancer. The company’s most advanced product candidate is an antibody-drug conjugate (ADC) that targets the protein CD70, which is expressed on the surface of many types of cancer cells.
– Prestige BioPharma Ltd ($KOSE:950210)
Prestige BioPharma Ltd is a biopharmaceutical company that focuses on the development, manufacture, and commercialization of innovative drugs for the treatment of cancer and other life-threatening diseases. The company has a market cap of 98.44B as of 2022 and a ROE of -28.18%. Prestige BioPharma’s products are designed to target specific molecular pathways that are involved in the development and progression of cancer. The company’s lead product candidates are PBP-101, an orally-available small molecule inhibitor of the checkpoint kinase 1 (Chk1) enzyme, and PBP-102, an antibody-drug conjugate that targets the epidermal growth factor receptor 2 (HER2).
Investors in KYMERA THERAPEUTICS were pleased to learn that for the second quarter of Fiscal Year 2023, the company reported total revenue of USD 16.5 million, a 43.4% year-over-year increase. The positive news caused the stock price to go up on August 3 2023, indicating that investors are optimistic about the company’s performance. This is a positive sign for KYMERA THERAPEUTICS, as they strive to maintain their growth trajectory.